The consequences of prostate cancer metastasis remain severe, with huge impact on the
mortality and overall quality of life of affected patients. Despite the convoluted interplay and …

The vascular endothelial growth factor (VEGF) family members, VEGF-A, placenta growth
factor (PlGF), and to a lesser extent VEGF-B, play an essential role in tumor-associated …

Prostate cancer is the most commonly diagnosed cancer among men in the Western world.
Although localized disease can be effectively treated with established surgical and …

Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is
controlled by the complicated and coordinated actions of pro-angiogenic factors and their …

The cardiovascular system comprises multiple cell types that possess the capacity to
modulate their phenotype in response to acute or chronic injury. Transcriptional and post …

Most anti-angiogenic therapies currently being evaluated target the vascular endothelial
growth factor (VEGF) pathway; however, the tumor vasculature can acquire resistance to …

Radiation therapy (RT) is commonly used for the treatment of localized prostate cancer
(PCa). However, cancer cells often develop resistance to radiation through unknown …

Abstract Background Prostate cancer (PCa) is a leading cause of cancer-related death in
males worldwide. Exacerbated inflammation and angiogenesis have been largely …

Purpose To explore how follicle-stimulating hormone (FSH) may contribute to
cardiovascular, metabolic, skeletal, and cognitive events in men treated for prostate cancer …

Prostate cancer progression is controlled by the androgen receptor and new blood vessel
formation, or angiogenesis, which promotes metastatic prostate cancer growth …